Company Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.
Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.
The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive.
In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications.
Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Dr. Praveen P. Tipirneni M.D. |
Contact Details
Address: 35 Gatehouse Drive A2 Waltham, Massachusetts 02451 United States | |
| Phone | (781) 996-0955 |
| Website | morphictx.com |
Stock Details
| Ticker Symbol | MORF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001679363 |
| CUSIP Number | 61775R105 |
| ISIN Number | US61775R1059 |
| Employer ID | 47-3878772 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce N. Rogers Ph.D. | President and Interim Principal Executive Officer |
| Dr. Timothy A. Springer Ph.D. | Founder, Independent Director and Member of Scientific Advisory Board |
| Dr. Marc Schegerin M.B.A., M.D. | Chief Financial Officer and Chief Operating Officer |
| Dr. Praveen P. Tipirneni M.D. | Chief Executive Officer, MD and Director (Leave of Absence) |
| Robert E. Farrell Jr., CPA | Senior Vice President of Finance and Chief Accounting Officer |
| Dr. Blaise Lippa Ph.D. | Chief Scientific Officer |
| William D. DeVaul Esq. | General Counsel and Secretary |
| Aaron Pelta | Senior Vice President of Business and Corporate Development |
| Joanne Gibbons | Senior Vice President of Regulatory Affairs |
| Dr. Simon Cooper MBBS | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 26, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Apr 26, 2024 | 424B5 | Filing |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2024 | 10-Q | Quarterly Report |
| Apr 25, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 8-K | Current Report |